BioTelemetry, Inc. (BEAT): Price and Financial Metrics


BioTelemetry, Inc. (BEAT): $4.66

0.40 (+9.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BEAT Stock Price Chart Interactive Chart >

Price chart for BEAT

BEAT Price/Volume Stats

Current price $4.66 52-week high $6.74
Prev. close $4.26 52-week low $1.12
Day low $4.20 Volume 279,700
Day high $4.80 Avg. volume 1,209,200
50-day MA $3.87 Dividend yield N/A
200-day MA $2.12 Market Cap 37.30M

BioTelemetry, Inc. (BEAT) Company Bio


BioTelemetry Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. It operates in three segments: Patient Services, Product, and Research Services. The company is based in Malvern, Pennsylvania.


BEAT Latest News Stream


Event/Time News Detail
Loading, please wait...

BEAT Latest Social Stream


Loading social stream, please wait...

View Full BEAT Social Stream

Latest BEAT News From Around the Web

Below are the latest news stories about HEARTBEAM INC that investors may wish to consider to help them evaluate BEAT as an investment opportunity.

HeartBeam Bags New Patent for Heart Attack Detection

Cardiac technology provider HeartBeam (NASDAQ:BEAT) has bagged a patent to detect heart attacks with its smartwatch-based monitor in the U.S. The development further builds up on BEAT’s 3D-vector electrocardiogram (VECG) platform and allows the company to make headways into the ischemia and Arrhythmia detection product lines BEAT estimates that the global wearables medical device market will reach $196 billion by 2030 and the new patent further enhances its capabilities. At the same time, the company is also focusing on furthering its HeartBeam AIMI and HeartBeam AIMIGo systems as well.    Shares of the company have climbed nearly 170% over the past six months.

Kailas Salunkhe on TipRanks | November 16, 2022

HeartBeam Snags New Patent For 12-Lead ECG Smartwatch-Based Monitor To Detect Heart Attacks

HeartBeam Inc (NASDAQ: BEAT) announced that its patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended to detect heart attacks and complex cardiac arrhythmias was allowed by the United States Patent and Trademark Office (USPTO). The company says that currently available wearables cannot provide a 12-lead ECG for heart attack detection, complex arrhythmia monitoring, or other cardiac disorders. HeartBeam's latest patent further expands on the company's anytime, anywhere ca

Yahoo | November 16, 2022

New HeartBeam Patent for 12-Lead Electrocardiogram (ECG) Smartwatch-based Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias

SANTA CLARA, Calif., November 16, 2022--New HeartBeam Patent for 12-Lead Electrocardiogram Smartwatch-based Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias

Yahoo | November 16, 2022

HeartBeam Reports Third Quarter 2022 Financial Results

SANTA CLARA, Calif., November 10, 2022--HeartBeam Reports Third Quarter 2022 Financial Results, Management to Host Webcast and Conference Call Today At 4:30 p.m. ET

Yahoo | November 10, 2022

HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif., October 25, 2022--HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern Time

Yahoo | October 25, 2022

Read More 'BEAT' Stories Here

BEAT Price Returns

1-mo 31.27%
3-mo 294.92%
6-mo 210.67%
1-year 8.37%
3-year N/A
5-year N/A
YTD 51.30%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7257 seconds.